Table 1. Clinical characteristics of cancer patients infected with COVID-19 according to outcome (N = 186).
| Total N = 186 (%) |
Survivors n = 159 (%) |
Non-survivors n = 27 (%) |
P value | |
|---|---|---|---|---|
| Age (years) | ||||
| Mean ± SD | 50.24 ± 15.77 | 50.22 ± 15.66 | 50.33 ± 16.75 | 0.974 |
| Median (IQR) | 52 (42–58.75) | 52 (42–58.5) | 53 (43.5–60) | 0.952 |
| Gender | ||||
| Male | 105 (56.45) | 89 (55.97) | 16 (59.26) | 0.835 |
| Female | 81 (43.55) | 70 (44.03) | 11 (40.74) | |
| Comorbidities | ||||
| Present | 86 (46.24) | 68 (42.77) | 18 (66.67) | 0.035 |
| Absent | 100 (53.76) | 91 (57.23) | 9 (33.33) | |
| Number of comorbidities in a patient | ||||
| No comorbidity | 100 (53.76) | 91 (57.23) | 9 (33.33) | 0.004 |
| Single | 47 (25.27) | 41 (25.79) | 6 (22.22) | |
| More than one | 39 (20.97) | 27 (16.98) | 12 (44.44) | |
| Type of comorbidities | ||||
| Cardiovascular disease | 11 (5.91) | 7 (4.40) | 4 (14.81) | 0.057 |
| Chronic obstructive pulmonary disease | 2 (1.08) | 2 (1.26) | 0 (0.00) | 1.000 |
| Diabetes | 34 (18.28) | 24 (15.09) | 10 (37.04) | 0.013 |
| Hypertension | 45 (24.19) | 36 (22.64) | 9 (33.33) | 0.233 |
| Thyroid (Hypo/Hyper) | 30 (16.13) | 26 (16.35) | 4 (14.81) | 1.000 |
| Other comorbidities | 5 (2.69) | 3 (1.89) | 2 (7.41) | 0.154 |
| Solid vs. Hematological cancer | ||||
| Solid | 153 (82.26) | 133 (83.65) | 20 (74.07) | 0.274 |
| Hematological | 33 (17.74) | 26 (16.35) | 7 (25.93) | |
| Cancer type | ||||
| Brain | 2 (1.08) | 2 (1.26) | 0 (0.00) | 0.095 |
| Head and neck | 33 (17.74) | 27 (16.98) | 6 (22.22) | |
| Breast | 19 (10.22) | 18 (11.32) | 1 (3.70) | |
| Thoracic | 17 (9.14) | 17 (10.69) | 0 (0.00) | |
| Musculoskeletal and skin | 6 (3.23) | 4 (2.52) | 2 (7.41) | |
| Gastrointestinal | 40 (21.51) | 31 (19.50) | 9 (33.33) | |
| Genitourinary and gynecologic | 36 (19.35) | 34 (21.38) | 2 (7.41) | |
| Hematological | 33 (17.74) | 26 (16.35) | 7 (25.93) | |
| Cancer spread | ||||
| Localized tumor | 58 (31.18) | 52 (32.70) | 6 (22.22) | 0.361 |
| Locally advanced | 78 (41.94) | 67 (42.14) | 11 (40.74) | |
| Metastatic | 50 (26.88) | 40 (25.16) | 10 (37.04) | |
| Cancer directed treatment within 1 month of COVID-19 infection | ||||
| Treated cases | 112 (60.22) | 94 (59.12) | 18 (66.67) | 0.528 |
| No treatment | 74 (39.78) | 65 (40.88) | 9 (33.33) | |
| Cancer treatment | ||||
| Surgery | 31 (16.67) | 27 (16.98) | 4 (14.81) | 1.000 |
| Chemotherapy | 69 (37.10) | 56 (35.22) | 13 (48.15) | 0.204 |
| Radiotherapy | 21 (11.29) | 20 (12.58) | 1 (3.70) | 0.320 |
| Targeted therapy | 6 (3.23) | 4 (2.52) | 2 (7.41) | 0.210 |
| Immunotherapy | 11 (5.91) | 10 (6.29) | 1 (3.70) | 1.000 |
| Severity of COVID-19 infection | ||||
| Mild | 134 (72.04) | 125 (78.62) | 9 (33.33) | <0.00001 |
| Moderate | 43 (23.12) | 32 (20.13) | 11 (40.74) | |
| Severe | 9 (4.84) | 2 (1.26) | 7 (25.93) | |
| Patients who received ventilator support | 12 (6.45) | 0 (0.00) | 12 (44.44) | 0.000 |